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Abstract: Parkinson’s disease (PD) is a highly debilitating motor disorder and is the second most
common neurodegenerative disease after Alzheimer’s disease. Its current method of diagnosis mainly
relies on subjective clinical rating scales in the presence of clinical motor features. Early detection of
PD is a known challenge as neuronal cell death may range from 50% to 80% when a patient is first
diagnosed with PD. Therefore, there is an urgent need to identify and develop biomarkers for early
detection of this progressive disease. This mini review focuses on the recent developments of
biofluid-based microRNAs (miRNAs) as molecular biomarkers for PD. A comprehensive list of
miRNA biomarkers found in blood, plasma, serum, and cerebral spinal fluid is presented. Challenges
and future perspectives of using these PD-related molecular biomarkers in a “real-world” clinical
setting are also discussed.
Keywords: Parkinson’s disease; biomarkers; microRNAs; circulating miRNAs; biofluid; blood;
serum; plasma; cerebral spinal fluid

1.

Introduction

Parkinson’s disease (PD) is an incurable, progressive movement disorder affecting
approximately one million Americans (www.pdf.org) and is the 14th leading cause of death in the
US (www.cdc.gov). The pathogenesis of PD involves the degeneration of neurons, especially
dopaminergic neurons in the substantia nigra of the midbrain [1], and the presence of Lewy
bodies/neuritis in various brain regions [2]. Deficiency of the nigro-striatal pathways can cause
dopamine depletion-specific symptoms such as motor dysfunctions and multiple non-motor clinical
issues. The clinical diagnosis of PD is based on the four cardinal symptoms: tremor, rigidity,
bradykinesia, and postural instability [3], which are delayed and subtle. Since the key pathology of
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PD occurs in the brainstem which is difficult to assess in living patients, it is challenging to monitor
PD progression in an unbiased and objective manner. Thus, developing reliable clinical diagnostic
methods that are feasible, objective, measurable, specific and sensitive for PD is essential to improve
the clinical management of the disease.
A molecular biomarker is a biological molecule found in blood, other bodily fluids or tissues
that can be measured as an indicator of a normal or abnormal biological process, or of a disease
condition. Molecular biomarkers can be used as a diagnostic or prognostic tool for a specific disease.
In PD, biochemical biomarkers which are heavily based on alpha-synuclein (SNCA), the primary
structural component of Lewy bodies, have been proposed in the past few years [4]. This mini review
will focus on the most recent development of non-SNCA, microRNA (miRNA)-based biomarkers
identified in various biofluids for PD diagnosis.
2. miRNAs as informative biomarkers for specific diseases
miRNAs are a family of short (18–22 nucleotides), single-stranded non-coding RNAs that act as
gene expression modulators at the post-transcriptional level to fine-tune the expression of specific
messenger RNAs (mRNAs) [5,6]. Many miRNAs can target multiple mRNAs by recognizing short,
specific complementary sequences in the mRNAs and control the expression of hundreds to
thousands of genes [7,8]. miRNA expression profiling has been used frequently to identify
biomarkers and/or molecular pathways associated with specific human diseases. miRNAs are also
known to be highly abundant, tissue-specific, quantifiable, highly stable with non-post process
modification, which are “ideal” characteristics of biomarkers. In neurodegeneration, although the
pathogenic mechanisms are complex and not fully defined, deregulation of miRNAs has been
increasingly recognized to play important roles in the process [9]. There is also emerging evidence
describing the important roles of miRNAs in neuronal processes such as neuronal differentiation and
neuroplasticity. miRNAs as potential clinical biomarkers for PD has been described extensively in
our previous review [10].
3.

Biofluids are excellent biomarker resources

Biological fluids or biofluids are liquids originating from human bodies. They are an excellent
source for biomarker research as their close proximity to cells can potentially reflect their
biochemical contents and hence the biological conditions of the cells [11]. Common biofluids used in
biomarker research include peripheral blood, blood serum or plasma, saliva, urine, and cerebral
spinal fluid (CSF). Deregulation of blood miRNAs has been significantly correlated with
disease-associated genetic variants [12]. Since biofluid sample collection is inexpensive, rapid,
simple, and minimally invasive (except for CSF), it has a large advantage over other solid or
semi-solid biospecimens for studying disease biomarkers.
4.

miRNAs detection in peripheral blood of PD patients

Blood is an ideal source for biomarkers because it can be obtained in a simple, fast, low-cost and
minimally invasive manner. The first report of peripheral blood-based miRNA biomarkers for PD was
demonstrated in 2011 by a quantitative real-time PCR (qRT-PCR) approach [13]. A set of 3 miRNAs
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(miR-1, miR-22*, and miR-29a) with lower miRNA expression was identified when compared
between de novo and treated PD vs. control and early-onset PD. A second set of 3 miRNAs
(miR-16-2*, miR-26a2*, and miR-30a) showed 50% higher expression in treated PD vs. control
subjects (Table 1). The second report applied a microarray approach to identify 18 under-expressed
miRNAs in peripheral blood mononuclear cells of PD vs. control [14]. The third report used a
combination of small RNA next-generation sequencing (small RNA-seq) and exon microarray
technologies to investigate miRNA expression in blood leukocytes (white blood cells) of healthy
controls as well as PD patients before and after deep brain stimulation (DBS) treatment [15]. A set of 5
miRNAs (miR-4293, miR-378c, miR-18b*, miR-20a, and miR-1249) that are under-expressed in PD
vs. DBS has inversed/higher expression in controls when compared with PD, suggesting both
treatment and disease related changes in miRNA expression. Interestingly, down-regulation of
miR-29a, miR-29c, miR-30c, and miR-19b can also be observed in white blood cells of PD DBS-off vs.
DBs-on patients and/or in the serum of PD vs. control (see Table 1 and cmiRNAs in plasma/serum
section below). Unfortunately, detection sensitivity of miRNA expression among biofluid types (i.e.,
peripheral blood vs. mononuclear cells vs. white blood cells vs. serum) could not be evaluated mainly
due to different technologies (i.e., qRT-PCT, microarray and next-generation sequencing) used among
these studies.
5.

The potential of circulating miRNAs (cmiRNAs) as disease-related biomarkers

The presence of circulating miRNAs (cmiRNAs) was first described in the serum of diffuse
large B-cell lymphoma patients [16]. Since then, many studies have shown that miRNAs exist not
only at the cellular level but also as circulating, cell-free miRNAs in serum, plasma, and CSF. There
are several hypotheses of how cmiRNAs can be released into circulatory systems: 1) direct leakage
of cellular miRNAs as by-products of tissue damage or apoptosis due to certain pathological
conditions (such as metastasis or inflammation), 2) active secretion by cells as free miRNAs with or
without cell stimulation, and 3) secretion in the form of cell-derived microvesicles (eg.
microparticles and exosomes), apoptotic bodies, miRNA-protected proteins (eg. Ago2 and NPM1) or
high-density lipoprotein [17–22].
Similar to miRNAs, cmiRNAs are highly stable and resistant to RNase activity, extreme pH and
temperature [23,24]. cmiRNA expression are also known to correlate with various human diseases,
especially cancers [17]. In PD, we performed a proof-of-concept study and first reported a panel of
four cmiRNA as potential PD biomarkers [25]. With high stability and capacity to reflect disease
status, cmiRNAs have great potential as molecular biomarkers for diagnosis and prognosis of
neurodegenerative diseases. Readers can further refer to a review by Sheinerman and Umansky [26]
on cmiRNAs biomarkers for various neurodegenerative diseases and three common approaches used
for such studies. In Alzheimer’s disease (AD), miRNA expression changes in brain and CSF have
provided insights into the disease pathways [27]. Therefore, besides their utility as disease
biomarkers, cmiRNA may provide new insights for the pathogenesis of PD.
6.

Identification of cmiRNA biomarkers in blood plasma/serum for PD
We published the first report of four plasma-based cmiRNAs (miR-1826, miR-450b-3p,

AIMS Medical Science

Volume 2, Issue 1, 15-25.

18

miR-626, and miR-505) as a panel of potential biomarkers for PD using Agilent microarrays
followed by a qRT-PCR approach [25]. A validation study using a new, independent cohort has been
carried out to confirm the reproducibility and robustness of these candidate biomarkers. One year
later, another group used the TaqMan low-density microarray cards and qRT-PCR and found
miR-331-5 significantly up-regulated in plasma of PD patients compared with healthy controls [28].
Both findings are mutually exclusive and could be explained by used of 1) different discovery
platforms which may have different detection sensitivities, 2) different statistical algorithms to
identify differentially-expressed cmiRNAs, and 3) treated PD patients in the formal and naïve PD
patients in the later report.
Recently, three additional studies on serum-based cmiRNA biomarkers for PD have been
reported. Four differentially-expressed cmiRNAs (miR-399-5p, miR-223*, miR-324-3p, and miR-24)
were identified and validated in PD and MSA (multiple system atrophy) vs. control subjects [29].
The same cmiRNAs (except miR-339-5p) were identified in PD vs. control, in addition to miR-30c
and miR-148b which were down-regulated. Interestingly, miR-30c was also found down-regulated in
the peripheral blood mononuclear cell of PD when compared with control. Another report used PD
and LRRK2 (leucine-rich repeat kinase 2) PD as discovery and first validation cohort to identify 4
statistically significant cmiRNAs (miR-29a, miR-29c, miR-19a, and miR-19b) in PD vs. control in a
second validation study [30]. Strikingly, down-regulation of miR-29a, miR-29c, miR-30c, and
miR-19b were also shown in previous blood-based biomarker studies [13,14]. Repeated detection of
similar miRNAs regardless of biofluid types and detection technologies make these miRNAs strong
biofluid-based biomarker candidates for PD which need to be validated. In another miRNA
expression profiling study using small next-generation sequencing on post mortem sera, 5
differentially-expressed cmiRNAs were identified between PD and control [31].
7.

cmiRNA expression is altered in PD’s CSF

Small RNA-seq was also recently used to detect 17 differentially-expressed cmiRNAs in post
mortem CSF of PD or AD patients vs. healthy controls [31]. Although one differentially-expressed
cmiRNA was identified in both CSF and serum for AD, there was no overlapping cmiRNA candidate
in CSF and serum from the same PD patients. This finding suggests that cmiRNA expression in
serum may not be corresponding to those in CSF which is directly connected to the central nervous
system; CSF and serum may not provide similar cmiRNA expression profiles in this case. Moreover,
the viability of cmiRNA expression in postmortem vs. fresh serum and CSF is relatively unknown
and worth investigation.
Table 1 summarizes the biofluid-based miRNA studies for PD mentioned above.
8.

Current limitations of biofluid-based miRNA biomarkers

Biofluid-based miRNA biomarker research for PD has been emerging rapidly. cmiRNAs are
envisioned to become potential biomarkers for early detection and progression of PD. However,
there are several impeding factors that may come into play. First, miRNAs usually exist in much
lower amounts in biofluids than tissues. Hence, depending on the sensitivity of the detection
techniques, they can remain undetected and be missed as potential biomarkers. Fortunately, recent
advancements of non-biased amplification and enrichment techniques have substantially improved
AIMS Medical Science
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Table 1. Biofluid-based miRNA expression studies in Parkinson’s disease.
miRNA
↓ miR-29a

Biofluid type
Peripheral

Sample size
15 PD vs. 8 CTR

blood

Sample type

Method

de novo PD +

qRT-PCR

levodopa/carbidopa treated vs.

(SYBR green)

Reference
Margis et al., 2011

CTR + early onset PD
White blood

PD (DBS-off) vs. PD (DBS-on)

cells
Serum

Small RNA-sequencing

7 PD vs. 6 CTR

10 PD, 10 LRRK2 PD vs. 10 CTR

(ABI SOLiD)
TaqMan Low

Discovery set:
PD vs. CTR

Soreq et al., 2013

Botta-Orfila et al., 2014

Density miRNA array v.2.0 A,

Validation set 1:

validation by qRT-PCR

20 PD, 20 LRRK2 PD vs. 20 CTR

(TaqMan)

Validation set 2: 65 PD vs. 65 CTR
↓ miR-29c

Peripheral

19 PD vs.13 CTR

PD vs. CTR

Exiqon

blood

miRCURY LNA array v.10.0,

mononuclear

validation by qRT-PCR

cell

(TaqMan)

Martins et al., 2011

Small RNA-sequencing
White blood

7 PD vs. 6 CTR

PD (DBS-off) vs. PD (DBS-on)

(ABI SOLiD)

Soreq et al., 2013

cell
TaqMan Low
Serum

Discovery set:

PD vs. CTR

Density miRNA array v.2.0 A,

10 PD, 10 LRRK2 PD vs. 10 CTR

validation by qRT-PCR

Validation set 1:

(TaqMan)

Botta-Orfila et al., 2014

20 PD, 20 LRRK2 PD vs. 20 CTR
Validation set 2: 65 PD vs. 65 CTR
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↓ miR-30c

Peripheral

19 PD vs.13 CTR

PD vs. CTR

Exiqon

blood

miRCURY LNA array v.10.0,

mononuclear

validation by qRT-PCR

cell

(TaqMan)

Martins et al., 2011

TaqMan Low
Serum

Discovery set:

PD vs. CTR

Density miRNA array v.3.0 A

6 PD, 6 MSA-P, 3 MSA-C vs. 5

and B,

CTR

validation by qRT-PCR

Validation set: 25 PD, 25 MSA, vs.

(TaqMan)

Vallelunga et al., 2014

25 CTR
↓ miR-19b

Peripheral

19 PD vs.13 CTR

PD vs. CTR

Exiqon

blood

miRCURY LNA array v.10.0,

mononuclear

validation by qRT-PCR

cell

(TaqMan)

Martins et al., 2011

TaqMan Low
Serum

Discovery set:

PD vs. CTR

Density miRNA array v.2.0 A,

10 PD, 10 LRRK2 PD vs. 10 CTR

validation by qRT-PCR

Validation set 1:

(TaqMan)

Botta-Orfila et al., 2014

20 PD, 20 LRRK2 PD vs. 20 CTR
Validation set 2: 65 PD vs. 65 CTR
↓ miR-1, miR-22*

Peripheral

15 PD vs. 8 CTR

blood

de novo PD +

qRT-PCR

levodopa/carbidopa treated vs.

(SYBR green)

Margis et al., 2011

CTR + early onset PD
↑ miR-16-2*, miR-26a2*,
levodopa/carbidopa treated vs.

miR-30a

CTR
↓ miR-335, miR-374a,

Peripheral

miR-199a-3p/miR-199b-3p,

blood

AIMS Medical Science
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miR-126*, miR-151-3p,

mononuclear

validation by qRT-PCR

miR-199a-5p, miR-151-5p,

cell

(TaqMan)

miR-126, miR-29b, miR-147,
miR-28-5p, miR-30b, miR-374b,
miR-301a, miR-26a
↓ miR-320a/b/c, miR-769,

White blood

miR-92b, miR-16

cell

7 PD vs. 6 CTR

PD (pre-DBS) vs.

CTR

Small RNA-sequencing

Soreq et al., 2013

(ABI SOLiD)

↑ miR-199b, miR-1274b,
miR-21, miR-150, miR-671,
miR-1249, miR-20a, miR-18b*,
miR-378c, miR-4293
↓ miR-4293, miR-378c,
miR-18b*, miR-424*, miR-20a,

PD (pre-DBS) vs. PD

miR-210, miR-1249, miR-93

(post-DBS)

↑ miR-4317, miR-143, miR-424
↓ miR-652, miR-15a*,
miR-376c, miR-143
↑ miR-423, miR-365, miR-486,
miR-1260, miR-218
PD (DBS-off) vs PD (DBS-on)
A panel of four miRNA

Plasma

Discovery set: 32 PD vs.32 CTR

PD (treated) vs. CTR

Agilent miRNA microarray

biomarkers

Replication set: 42 PD vs.30 CTR

v.3,

↑ miR-1826,

Validation set: 30 PD, 4 MSA, 5 PSP

validation by qRT-PCR

↓ miR-450b-3p

vs. 8 CTR

(TaqMan)

Khoo et al., 2012

↑ miR-626, miR-505
↑ miR-331-5p

Plasma

31 PD vs. 25 CTR

PD (non-treated) vs. CTR

TaqMan Low Density miRNA

Cardo et al., 2013

array (3 pools of PD and
CTR),
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then qRT-PCR (TaqMan)
Serum

↓ miR-339-5p

Discovery set:

PD + MSA vs. CTR

TaqMan Low

↑ miR-223*, miR-324-3p,

6 PD, 6 MSA-P, 3 MSA-C vs. 5 CTR

Density miRNA array v.3.0 A

miR-24

Validation set: 25 PD, 25 MSA, vs.

and B,

25 CTR

validation by qRT-PCR

↓ miR-148b

PD vs. CTR

(TaqMan)

PD vs. CTR

TaqMan Low

Vallelunga et al., 2014

↑ miR-223*, miR-324-3p,
miR-24
↓ miR-19a

Serum

Discovery set:
10 PD, 10 LRRK2 PD vs. 10 CTR

Density miRNA array v.2.0 A,

Validation set 1:

validation by qRT-PCR

20 PD, 20 LRRK2 PD vs. 20 CTR

(TaqMan)

Botta-Orfila et al., 2014

Validation set 2: 65 PD vs. 65 CTR

50 PD vs. 62 CTR

↓ miR-16-2-3p, miR-1294

Serum

↑ miR-338-3p, miR-30e-3p,

(post mortem)

PD vs.

CTR

Small RNA Sequencing

Burgos et al., 2014

(Illumina HiSeq2000)

miR-30a-3p
↓ miR-132-5p, miR-485-5p,

CSF

miR-127-3p, miR-128,

(post mortem)

57 PD vs. 65 CTR

PD vs. CTR

miR-409-3p, miR-433, miR-370,
miR-431-3p, miR-873-3p,
miR-136-3p, miR-212-3p,
miR-10a-5p, miR-1224-5p,
miR-4448
↑ miR-19a-3p, miR-19b-3p,
let-7g-3p
PD: Parkinson’s disease; CTR: healthy control; PSP: progressive supranuclear palsy; MSA: multiple system atrophy; LRRK2 PD: G2019S mutation in PD;
DBS: Deep brain stimulation; ↓: down-regulated miRNA expression; ↑: up-regulated miRNA expression.
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the detection sensitivity of miRNA expression. Second, biomarker research is known for its
complexity and difficulty in correlating different biomarker data from different reports. As shown in
Table 1, biomarkers in bodily fluids are screened and analyzed by a variety of techniques. Variations
may also involve sample collection and storage, sample preparation, data normalization and data
analysis [10]. Therefore, a unifying method and/or technique should be applied for each specific
biomarker in general. However, in a “real-world” clinical setting, standardization from the beginning
of sample collection to assay processes may not be feasible or realistic. This also brings us to the
third limitation where either small or no validation studies were performed to confirm the
reproducibility and robustness of these biofluid-based biomarker candidates and its assays; this
drawback has further delayed the incorporation of molecular biomarkers into routine preclinical or
clinical applications. Fourth, the presence of miRNAs in biological fluids as a disease indicator
remains a subject of considerable debate. Although deregulation of miRNAs has been increasingly
recognized to play important roles in neurodegeneration [9], the potential of utilizing miRNAs to
reflect pathogenic changes in the brain needs to be further investigated and validated.
9.

Future perspectives

This mini review shows that miRNAs in bodily fluids hold promise as potential molecular
biomarkers for PD. Unique characteristics of miRNAs and cmiRNAs make them highly attractive as
molecular biomarkers. Follow-up validation studies and standardization are critical to ensure
successful development of sensitive and specific biomarkers for PD. The finding of stable cmiRNAs
in biofluids suggests their possible function as mediators in cell-cell communication in response to
biological stimuli [32]. Thus, it is possible that cmiRNAs in serum or plasma may directly or
indirectly reflect the pathological status of the brain. It is also known that miRNAs can be
transported by exosomes which are lipid microvesicles of endocytic origin secreted by many cell
types, including neurons, astrocytes, oligodendrocytes, and microglia [33–36]. Recent evidence has
shown the involvement of exosomes in the pathogenesis of PD [37]. Although the association of
exosome-based miRNAs in neurodegeneration has not been established, it is worth future
investigation.
In AD, cmiRNAs in CSF and serum have been identified to correlate with the severity of
disease such as Braak stages, neurofibrillary tangle and plaque-density scores [27,31]. Hence, future
investigation of cmiRNA expression in correlation with PD severity (e.g. SNCA accumulation or
Lewy bodies) may accelerate discovery of progression biomarkers for PD. In summary, establishing
and validating biofluid-based miRNA biomarkers may facilitate the development of objective
diagnostic and prognostic molecular tools for PD to translate basic research discovery to clinical
setting.
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